The ad goes on to tout Hims & Hers' weight loss drugs as less expensive alternatives to medications like Ozempic and Wegovy, ...

Hims & Hers has shown impressive revenue growth, accelerating from 46% to 77%. Read why I downgrade HIMS stock from buy to ...

Hims & Hers Health (NYSE: HIMS) is surging today. The stock is up 19%, and this is part of a broader 482.5% rally in the past year that has carried this telehealth company to nosebleed levels. Here’s ...

When it comes to achieving healthy body weight, some men might look to what’s average and use that as their goal. For ...

Hims has a great deal of meme potential, which could benefit the company by effectively acting as free advertising. Read more ...

Telehealth company Hims & Hers Health (HIMS) recently stirred up controversy with its ad promoting its compounded weight-loss ...

Hims and Hers are being scrutinized after running a Super Bowl ad, claiming to be a less expensive alternative to Ozempic and ...

Hims & Hers Health, Inc. (HIMS) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near ...

We recently compiled a list of the 12 Best Booming Stocks to Invest in Now. In this article, we are going to take a look at ...

The facts discussed here and much other information on Zacks.com might help determine whether or not it's worthwhile paying attention to the market buzz about Hims & Hers Health. However ...

All products are independently selected by our editors. If you buy something, we may earn an affiliate commission. Nobody really looks forward to reading a Hims review. But hair loss comes for us ...